Interventional Strategies to Delay Aging-Related Dysfunctions of the Musculoskeletal System by Fukase, Naomasa et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Interventional Strategies to Delay 
Aging-Related Dysfunctions of the 
Musculoskeletal System
Naomasa Fukase, Ingrid K. Stake, Yoichi Murata, 
William S. Hambright, Sudheer Ravuri, 
Marc J. Philippon and Johnny Huard
Abstract
Aging affects bones, cartilage, muscles, and other connective tissue in the 
musculoskeletal system, leading to numerous age-related pathologies including 
osteoporosis, osteoarthritis, and sarcopenia. Understanding healthy aging may 
therefore open new therapeutic targets, thereby leading to the development of 
novel approaches to prevent several age-related orthopaedic diseases. It is well 
recognized that aging-related stem cell depletion and dysfunction leads to reduced 
regenerative capacity in various musculoskeletal tissues. However, more recent 
evidence suggests that dysregulated autophagy and cellular senescence might be 
fundamental mechanisms associated with aging-related musculoskeletal decline. 
The mammalian/mechanical target of Rapamycin (mTOR) is known to be an 
essential negative regulator of autophagy, and its inhibition has been demonstrated 
to promote longevity in numerous species. Besides, several reports demonstrate that 
selective elimination of senescent cells and their cognate Senescence-Associated 
Secretory Phenotype (SASP) can mitigate musculoskeletal tissue decline. Therefore, 
senolytic drugs/agents that can specifically target senescent cells, may offer a 
novel therapeutic strategy to treat a litany of age-related orthopaedic conditions. 
This chapter focuses on osteoarthritis and osteoporosis, very common debilitating 
orthopaedic conditions, and reviews current concepts highlighting new therapeutic 
strategies, including the mTOR inhibitors, senolytic agents, and mesenchymal stem 
cell (MSC)-based therapies.
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1. Introduction
Aging is a process of progressive loss of physiological function and reserve, 
characterized by cellular senescence, stem cell exhaustion, DNA damage, telo-
mere attrition, and deregulated nutrient sensing [1]. It is well known that aging-
related stem cell depletion and dysfunction leads to reduced tissue regenerative 
capacity in various stem cell populations. Osteoarthritis (OA) and osteoporosis 
(OP) are two common aging-related skeletal diseases that influence the quality of 
life in the elderly.
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Osteoarthritis is one of the most common chronic degenerative joint diseases 
that cause joint pain and dysfunction. Multiple factors, including mechanical, 
genetic, and aging-related factors, are involved in the development of OA [2]. At the 
cellular level, it is characterized by loss of tissue cellularity, and phenotypic changes 
to chondrocytes, and subsequent damage to the extracellular matrix (ECM) [3]. 
Chondrocytes are resident cells in cartilage tissue and are involved in both the syn-
thesis and turnover of the ECM [4]; therefore, maintaining chondrocyte health is 
an essential factor in preventing articular cartilage degeneration. With age, articular 
cartilage ECM degrades and remodels with the fragmentation of the principal 
proteoglycan protein aggrecan, chondroitin sulfate, and relative increases in keratan 
sulfate and hyaluronan deposition [5, 6]. Chondrocytes also exhibit an autolytic 
phenotype causing the proteolytic cleavage of various collagen molecules [7]. 
Collectively, such ECM perturbations during aging lead to a concomitant decrease 
in water content, affecting tensile strength of the cartilage and transmission of load.
Osteoporosis is a systemic bone degenerative disease characterized by a progres-
sive loss of bone mass accompanied by a significant reduction in the mechanical 
strength of the bones [8]. Bone loss during aging is also characterized by changes 
in bone shape, mineral content, adiposity, mineral turnover, and reduction in bone 
forming osteoblasts [9, 10]. Another bi-product of aging is a reduction of bone 
healing capacity exacerbated by chronic inflammation inherent with advancing age 
[11] that also disrupts homeostatic interactions between signaling factors and bone 
cells, resulting in a state of dysregulated remodeling and bone turnover. Thus, aging 
is one of the factors most closely associated with the development of OP [12]. Brittle 
bones, as a result of OP in the elderly have been known to cause fractures triggered 
by minor trauma, significantly worsening the quality of life and even reduce life 
expectancy [13].
Recent research is beginning to unravel the mechanisms of how aging 
makes bones and joints more susceptible to the development of these diseases. 
Understanding the underlying mechanisms may provide new treatments to delay or 
prevent the development of these aging-related orthopedic disorders. This chapter 
focuses on OA and OP among aging-related dysfunctions of the skeletal system and 
reviews current concepts on new therapeutic strategies, especially the mammalian/
mechanistic target of Rapamycin (mTOR) inhibitors, senolytic agents, and 
mesenchymal stem cells (MSCs).
2. Autophagy as a therapeutic target in aging-related orthopedic diseases
2.1 Autophagy and mTOR in OA
Autophagy is an essential homeostatic process for the clearance of damaged 
intracellular components [14]. It is conserved evolutionarily across species and 
is commonly known to be activated under stress conditions, including nutrient-
deficiency, to generate energy [15]. When cells face nutritional stress, the 
autophagy pathway is activated to degrade unnecessary intracellular components 
while maintaining only the minimum essential components to prevent energy loss. 
Recent evidence has linked autophagy in the pathophysiology of OA. Inhibition of 
autophagy has been reported to promote the expression of OA-like genes induced 
by interleukin-1β (IL-1β), whereas activation of autophagy reduces the intracel-
lular reactive oxygen species (ROS) by removing damaged mitochondria, thereby 
protecting chondrocytes from OA-like changes [16]. During aging and especially in 
OA, autophagic flux is diminished, likely due to decreases in autophagy regulator 
genes ULK1, beclin-1, and LC [17], and is associated with increased chondrocyte 
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apoptosis and mitochondrial dysfunction [18]. These results suggested that 
increased autophagy is an adaptive response to protect chondrocytes from stress 
and that autophagy regulates OA-like gene expression changes via the modulation 
of apoptosis and ROS [19]. Thus, the modulators of autophagy, such as mTOR, may 
represent key targets to for the treatment of OA.
mTOR is a serine/threonine protein kinase that is a negative regulator of autoph-
agy, integrates inputs from nutrients and growth factors, and regulates many basic 
cellular processes through two distinct protein complexes, mTORC1 and mTORC2. 
mTOR is an established longevity axis, and its inhibition either pharmacologically or 
genetically, has been demonstrated to extend lifespan in numerous species [20–22]. 
Recent studies suggest that mTOR plays an important role in cartilage growth and 
development, alters articular cartilage homeostasis, and contributes significantly 
to the cartilage degenerative process associated with OA [23] mTOR expression has 
been shown to be elevated in OA models and has been associated with increased 
chondrocyte apoptosis [24]. Given that mTOR is a negative regulator of autophagy, 
the deleterious effects of age-associated increases in mTOR activity can be linked to 
decreased autophagy in chondrocytes during OA. Pre-clinical experiments in rat OA 
models have also shown that suppressing the PI3K/AKT/mTOR signaling pathway 
promotes articular chondrocyte autophagy and alleviates inflammation [25]. Both 
pharmacological and genetic approaches for inhibiting mTOR signaling have been 
shown to reduce the severity of OA in pre-clinical animal models [24–27].
2.2 Pre-clinical studies targeting mTOR for the treatment of OA
Rapamycin is the oldest known natural mTOR inhibitor that has been tradition-
ally used clinically as an immunosuppressive agent [28]. Rapamycin acts through 
binding of FK506-binding proteins and primarily destabilizes mTORC1, but to 
some extent can prevent the phosphorylation of downstream targets of mTOR1 
[29–31]. Since its FDA approval in 1999, Rapamycin has been used by millions of 
patients. There is a litany of clinical evidence suggesting that Rapamycin is a safe 
and effective drug with few side effects for which all are reversible [31, 32].
Interestingly, recent studies have shown that Rapamycin acts to activate 
human chondrocyte autophagy in vitro primarily by inhibiting mTOR com-
plex 1 (mTORC1) and suppressing the development of OA-like changes [19]. 
Furthermore, systemic administration of Rapamycin has been shown to reduce the 
severity of OA through activation of autophagy in a mouse model [26].
Our group has found that intra-articular injection of Rapamycin was a safe and 
effective therapeutic delivery method to protect articular cartilage from osteoar-
thritic changes in a mouse model of OA [27]. On the other hand, deletion of mTOR 
has been shown to up-regulate autophagy and protect mice from OA in inducible 
cartilage-specific mTOR knockout mice [24]. Torin 1, a selective ATP-competitive 
inhibitor of mTOR, which can cause induction of autophagy, is also regarded as a 
potent inhibitor of both mTORC1 and mTORC2. In a rabbit model of OA, intra-
articular injection of Torin 1 was shown to reduce articular cartilage degeneration 
[33, 34]. Another agent with demonstrated ability to reduce mTOR activity is 
Metformin, which is FDA-approved for the treatment of type 2 diabetes [35]. 
Metformin has been shown to activate 5’ AMP-activated protein kinase (AMPK), 
a negative regulator of mTOR. Recently, Metformin has also been shown to inhibit 
cartilage degeneration in OA mouse models by downregulating mTOR [36]. In 
another murine study, Metformin was shown to reduce OA structural worsening 
and reduce pain scores [37]. Therefore, multiple lines of evidence support the 
theory of mTOR signaling as a promising therapeutic target for OA, mainly through 
the modulation of autophagy.
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2.3 Autophagy and mTOR in OP
Multiple proteins involved in the autophagic activity are essential for the sur-
vival, differentiation, and function of bone cells, including osteocytes, osteoblasts, 
and osteoclasts [38]. Autophagy is critical for the necessary crosstalk between 
bone resident cells and thus plays a critical role in the signaling dynamics for bone 
synthesis (osteoblasts) and degradation (osteoclasts). Dysregulation in the level of 
autophagic activity has been found to disrupt the balance between bone formation 
and bone resorption linked to the onset and progression of OP [38–42]. In addition, 
autophagy plays an important role in MSC function and lineage determination from 
adipogenesis to osteoblastogenesis, [43] and it has been linked to the increased 
adipogenic differentiation in bone MSCs [44]. Autophagic activity is known to 
decrease with age, especially in bone cells, [45] hence the regulation of autophagic 
activity is considered a promising strategy for the prevention and treatment of OP 
[14, 46].
Osteoblast dysfunction is a significant cause of aging-related bone loss, but the 
mechanisms underlying osteoblast dysfunction with aging are not fully elucidated. 
mTOR has been shown, through in-vitro studies, to regulate osteogenic genes 
(Runx2, Osterix), stemness genes (Oct3/4, Nanog), and mineralization through 
alkaline phosphatase production [47].
2.4 Pre-clinical studies targeting mTOR for the treatment of OP
Several studies have investigated the efficacy of targeting mTOR for the 
treatment of OP. Systemic delivery of autophagy modulators such as Rapamycin 
and its analogs have been tested in a number of animal models. In a study using 
24-month-old rats, micro-CT showed that Rapamycin effectively inhibited aging-
related bone loss in trabecular bone. In this study, Rapamycin treatment resulted 
in a significant decrease in the number of osteoclasts, as well as the induction 
of osteoclast autophagy and a decrease in osteocyte apoptosis compared to the 
control group [48]. Besides, mTORC2 signaling stimulates osteoblast differentia-
tion and is involved in aging-related OP [49]. The expression of Rictor, a specific 
component of mTORC2, is decreased in osteoblasts during aging, which may 
contribute to aging-related bone loss, and deletion of Rictor in osteoblasts has 
been shown to accelerate aging-related bone loss in a mouse model [49]. The use 
of Everolimus, a Rapamycin analog and predominant mTORC1 inhibitor, has been 
shown to protect against OP onset in ovariectomized rats through the reduc-
tion of osteoclast formation and cathepsin K mediated matrix degradation [50]. 
Rapamycin has also been shown to reduce the severity of age-related bone condi-
tions in trabecular bones of aged male rats by activating osteocyte autophagy [48]. 
Taken together, mTOR may play a critical role in aging-related OP and represents a 
promising therapeutic target.
3.  Cellular senescence: a new therapeutic strategy for the treatment of 
aging-related musculoskeletal decline
3.1 Senescent cells
Senescent cells play a vital role in the aging process and promote degenerative 
diseases, geriatric syndromes, and potentially malignancy through the production 
of a Senescence Associated Secretory Phenotype (SASP) characterized by pro-
inflammatory and catabolic anti-regenerative factors [51]. Senescence is a state 
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defined by replicative arrest and resistance to apoptosis with altered metabolic 
activity, and several factors, often related to cell or tissue damage, can induce 
senescence, including DNA lesions, mechanical/shear stress, reactive metabo-
lites, proteotoxic stress, and inflammation [51]. When present, these factors 
can activate one or more pathways through the p16Ink4a/retinoblastoma protein, 
p53/p21Cip1, or other transcription factor cascades, resulting in cell cycle arrest, 
metabolic shifts, altered gene expression, and the production of deleterious SASP 
factors [51, 52].
Senescent cells accumulate in tissues throughout the lifespan and are normally 
removed by the immune system [53]. However, inefficient removal due to chronic 
stress or pathology may exceed the capacity of the immune system, especially during 
aging, where chronic inflammation disrupts the homeostatic immunologic clearance 
mechanisms [51, 53–55]. SASP factors from senescent cells are especially deleteri-
ous and include various cytokines, chemokines proteins, growth factors, and tissue 
degrading matrix metalloproteinases (MMPs) [51, 56, 57]. These factors stimulate 
inflammation, ECM degradation, fibrosis, and secondary senescence in surrounding 
cells [51, 54, 58]. SASP components can be cell-type specific, and senescence triggers 
are influenced by several factors, including hormones, stress, drugs, and pathogens 
[51]. A schema showing the association between senescence and OA is shown in 
Figure 1. With an increased number of senescent cells, a higher amount of secreted 
SASP components may cause an inflammatory, apoptotic, and cell- and tissue-
destructing effect, eventually resulting in aging and chronic diseases. For these 
reasons, targeting senescent cells has garnered significant attention for the treatment 
of age-associated pathologies, especially musculoskeletal conditions [59].
According to the “geroscience hypothesis” [60], targeting senescent cells is 
appealing as they are a fundamental property of aging and may thus delay or 
reverse physiological consequences of the aging process or the development 
of aging-related diseases [51, 58]. However, there are no established markers 
Figure 1. 
Schema of the association between senescence and OA. Aging is accompanied by the secretion of the senescence-
associated secretory phenotype (SASP), including various chemokines, cytokines, proteases, and growth 
factors, which act alone or together to cause degenerative changes in the subchondral bone, synovial fold, and 
articular cartilage, ultimately leading to OA. IL, interleukin; RANKL, Receptor activator of NF-κβ ligand; 
TNF, tumor necrosis factor; MMPs, Matrix metalloproteinases; TGFβ, Transforming Growth Factor-β; IGF, 
insulin-like growth factor; OPN, Osteopontin; SOST, Sclerostin; OC, Osteocalcin; PGE, Prostaglandin E; 
BMPs, Bone morphogenetic proteins; GM-CSF, Granulocyte Macrophage colony-stimulating Factor; CCL, 
C-C motif chemokine ligand; VEGF, vascular endothelial growth factor; GMCSF, Granulocyte-macrophage-
colonystimulating factor; ADAMTS, A disintegrin and metalloproteinase with thrombospondin motifs; GROα, 
Growth-related oncogene-α; CS-846, The 846 epitope of chondroitin sulfate; COMP, Cartilage oligomeric 
matrix protein; HA, Hyaluronic acid.
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universally specific to senescent cells [51, 54]. Higher expression of p16Ink4a and 
p21Cip1 usually occur in senescent cells [61, 62]. One of the prominent hallmarks, 
however, is resistance to apoptosis [63]. Zhu et al. reported that senescent cells anti 
apoptotic pathway (SCAP) networks are expressed at higher levels compared to 
non-senescent cells, playing an essential role in the resistance to apoptosis [64]. Of 
39 transcripts targeted by small interfering RNAs (siRNAs), six transcripts (ephrin 
ligand (EFN) B1, EFNB3, p21Cip1, plasminogen-activated inhibitor-2 (PAI-2), 
phosphatidylinositol-4,5-bisphosphate 3-kinase delta catalytic subunit (PI3KCD), 
and BCL-xL) were found to downregulate SCAPs and elicit apoptosis in senescent 
cells. Targeting several SCAP pathways may also be necessary for senescent cell 
removal and may further increase specificity for senescent cells while not affecting 
healthy non-senescent cells [51, 64].
3.2 Treatment of aging-related skeletal diseases with senolytic agents
The use of senolytic agents is a promising approach to delay aging and reduce 
the severity of chronic diseases through senescent cell depletion [58]. Various drugs 
have now been characterized that demonstrate the ability to eliminate senescent 
cells, namely through reduction in anti-apoptotic signaling [65]. For example, 
Fisetin is a recently characterized senolytic flavonoid phytonutrient found in fruits 
and vegetables that can extend health and lifespan in naturally aged and progeroid 
mice [66]. Yousefzadeh et al. tested ten flavonoids and found that Fisetin demon-
strated the highest senolytic activity [66]. Fisetin has been found to target senes-
cence associated pathways such as SIRT1, [67] BCL-2/BCL-XL, [68, 69] HIF-1α, 
[70] p53/MDM2, [69, 71] and AKT, [69, 72] leading to elimination of senescent 
cells. However, it also has the ability to reduce oxidative stress via SIRT1/Nrf2,  
[73] decrease mitochondria-derived ROS via inhibition of GSK3β, [73] and exhibit 
anti-inflammatory effects. Another example, Metformin, is a widely prescribed 
anti-diabetic drug with lifespan extending effects in mice, [74] and exhibits 
senolytic activity via targeting some similar, but also several different senescence 
associated pathways from Fisetin. Metformin is known to activate AMPK, which 
indirectly inhibits mTOR, the most established nutrient sensing longevity regulat-
ing pathway to date [75]. In addition, Metformin reduces oxidative stress and SASP 
related inflammation through inhibition of NF-kB activity, [75, 76] and inhibits 
insulin and IGF-1 signaling, which are all hyperactivated during aging [75, 77]. 
Thus, many senolytic drugs have pleiotropic effects that mitigate age-related cel-
lular and physiological dysfunction. Furthermore, senolytic agents can be admin-
istered intermittently since they do not interfere with a receptor or an enzyme, 
thereby reducing potential side effects [54]. Accordingly, intermittent treatment 
may maintain the positive effect of senescent cells on wound healing, cancer 
prevention, and homeostasis [78–81].
The list of agents with senolytic potential is growing. Zhu et al. tested 46 
potential senolytic agents and found that Dasatinib and Quercetin demonstrated 
particularly good results in terms of reducing senescent cells [64]. Dasatinib is a 
tyrosine kinase inhibitor used in cancer treatment and is known to interfere with 
ephrin-dependent suppression of apoptosis [82, 83]. Quercetin is a naturally occur-
ring flavonoid found in several fruits and vegetables known to inhibit PI3K, kinases, 
and serpines [64]. Noteworthy, Dasatinib, in combination with Quercetin was able 
to induce apoptosis more effectively in a broader range of senescent cell types than 
either one alone [84]. Navitoclax, a lymphoma drug, inhibits the anti-apoptotic 
proteins in the Bcl-2 family and has been used in cancer treatment [85]. It has 
demonstrated senolytic effects in several cell types in vitro. However, in aged mice, 
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it demonstrated reduced trabecular bone volume and impaired osteoblast function 
[86]. Additionally, Navitoclax is directed against a small number of SCAP network 
molecules and has shown poor specificity for senescent cells with increased risk of 
side effects, including thrombocytopenia due to its effect on platelets [87]. Thus, 
not all drugs with senolytic ability are clinically suitable due to a range of potential 
side effects or drug-to-drug interactions with existing medications. However, the 
ability to transiently dose and the existence of natural compounds with favorable 
safety profiles (ex. Fisetin, Quercetin, Metformin, Rapamycin, Geldanamycin etc.) 
offer the potential for continuous administration.
Some senolytic agents have been tested for their effects on the musculoskeletal 
system, demonstrating a potential to reduce aging-related diseases and conditions. 
Here we will focus on the use of senolytic agents in the setting of OA and OP.
3.2.1 Agents for the treatment of OA
3.2.1.1 Pre-clinical studies of senolytic agents for the treatment of OA
Senescent cells have long been associated with OA [88, 89]. Articular cartilage 
from patients with advanced OA have a significant number of senescent chon-
drocytes, [90, 91] with canonical hallmarks of senescence, including metabolic 
dysfunction, telomere attrition, and decreased autophagy [51, 52]. Aging-related 
oxidative stress, in addition to mechanical stress from cartilage loading, may 
contribute to chondrocyte senescence [88]. The cell’s ability to compensate for 
stress reduces with aging, and an accumulation of senescent cells results in a loss of 
homeostasis with increased secretion of inflammatory mediators, reduced matrix 
synthesis, and impaired response to growth factor stimulation. This may result in 
the development of OA. The link between senescence and OA was demonstrated 
by Xu et al. [92]. Three months after injection of senescent cells into the knee joint 
of mice, they found changes suggestive of OA, including damage to cartilage and 
menisci, osteophytes, and changes of the subchondral bone. The mice also dem-
onstrated pain and reduced function. These changes were not found in the control 
group, suggesting that high concentrations of senescent cells may act detrimentally 
on the articular cartilage homeostasis [92]. In addition, other groups have shown 
that local clearance of senescent cells genetically within the intra-articular space 
significantly reduced the development of injury-induced OA and promoted a pro-
regenerative environment [93].
The role of the senescence marker p16Ink4a was studied by Diekman et al. [94]. 
The mRNA expression of p16Ink4a was significantly higher in aged mice than in 
young mice, which inhibited chondrocyte proliferation. Interestingly, SASP fac-
tors correlated to the expression of p16Ink4a regardless of age; however, inhibition 
of p16Ink4a did not affect the SASP production or prevent the development of 
age-induced or post-traumatic OA of the knee joint. In another study, Zheng et al. 
studied the effect of Fisetin in vitro on IL-1β stimulated human chondrocytes and 
in vivo in murine OA models [95]. In the IL-1β stimulated human chondrocytes, 
Fisetin increased the expression of the enzyme silent information regulator (SIRT) 
1 and thereby inhibited the IL-1β induced increased levels of NO, PGE2, IL-6, TNF-
α. Additionally, the mRNA expression and the protein levels of the IL-1β induced 
iNOs, COX-2, MMP-3, MMP-13, ADAMTS-5 were inhibited, and the induced 
downregulation of SOX-9, aggrecan, and collagen-II degradation was increased. 
Sirtinol, an inhibitor of SIRT1, reversed the effects of Fisetin on chondrocytes. In 
the murine OA models, Fisetin demonstrated findings of attenuated progression of 
OA, thus highlighting its potential as a senolytic treatment for OA [67].
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SIRT1 has been reported to be important for cartilage homeostasis by promoting 
chondrocyte survival and ECM homeostasis [96]. However, data suggest that SIRT1 
is proteolytically inactivated during OA [97]. Batshon et al. demonstrated that the 
NT/CT SIRT1 fragments were found in serum, and an elevated serum NT/CT SIRT1 
ratio was associated with both post-traumatic and aging-related OA in mice [98]. A 
similar increase was found in humans with OA. Further analysis confirmed that the 
elevated NT/CT SIRT1 fragments are derived from chondrocytes. Senolytic treat-
ment decreased the serum NT/CT SIRT1 ratio and enhanced the intracellular level 
of SIRT1 in chondrocytes, which correlated with the reduced severity of OA. Dai 
et al. showed that the combination of Dasatinib and Quercetin to remove senescent 
chondroprogenitor cells can inhibit SASP formation and thus effectively improve 
the results of distraction arthroplasty in vitro and in vivo [84]. Recently, it has also 
been found that intra-articular injection of Navitoclax in post-traumatic OA rats 
can reduce inflammation, remove senescent chondrocytes in OA, and promote 
chondrogenic phenotype [99]. Jeon et al. recently tested UBX0101, a senolytic that 
was found to selectively eliminate senescent cells, found that intra-articular admin-
istration of UBX0101 reduced the incidence of post-traumatic OA and associated 
pain resulting in the development of a prochondrogenic environment [93]. Faust 
et al. reported that IL-17 expression was increased in mice with post-traumatic OA 
and in aged mice, and that there was a correlation between senescent cells and IL-17. 
In their study, senescent fibroblasts increased the level of Th17 cells, when stimu-
lated by IL-6, IL-1β, and TGF-β, and Th17 cells induced senescence in fibroblasts. 
Inhibition of senescent cells in mice reduced Th17 cells and IL-17; however, both 
local (UBX0101) and systemic (Navitoclax) senolytic treatment was necessary to 
reduce cartilage degeneration in aged mice [100]. These findings would provide 
markers for diagnostic screening and targets for senolytic agents in the treat-
ment of OA.
3.2.1.2 Clinical studies of senolytic agents for the treatment of OA
Several Phase 1 and 2 clinical trials on senolytic agents for the treatment of OA 
are underway (ClinicalTrials.gov ID: NCT03513016, NCT04229225, NCT04129944, 
NCT04210986). At our clinic, we are carrying out multiple Phase I/II randomized 
controlled trials examining the efficacy of Fisetin in the setting of knee OA with 
(NCT04210986) or without co-treatment with bone marrow concentrate (BMC). 
In these studies, patients diagnosed with Kellgren-Lawrence grade II-IV knee OA 
and a numerical rating scale (NRS) pain score of 4–10 are included. Outcome 
measures include safety and tolerability of Fisetin administration for two days on 
and 28 days off (20 mg/kg), as well as patient report pain and function indices, OA 
and SASP related biomarkers, and magnetic resonance imaging (MRI) of cartilage. 
There have also been multiple other trials using the senolytic agent UBX0101 car-
ried out by Unity Biotechnology (NCT04229225, NCT04129944, NCT03513016, 
NCT03100799). Many of these studies demonstrated the safety and tolerability of 
UBX0101 injected intra-articularly with different dosing regimens (single- vs. multi-
dose, ascending doses) (https://doi.org/10.1016/j.joca.2020.02.752). However, none 
of the studies demonstrated a significant reduction in pain up to 12 weeks as assessed 
by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
scoring system. A long-term outcome trial measuring safety and tolerability of 
UBX0101 at one year was also terminated, failing to meet primary or secondary 
objectives. (https://clinicaltrials.gov/ct2/show/NCT04349956) While many of these 
trials are underway, senolytic treatment for OA may nonetheless be a potentially 
groundbreaking novel treatment strategy to ameliorate the onset and/or progression 
of OA. More studies are needed to better understand therapeutic delivery (oral vs. 
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intra-articular), dosing, and senolytic drug of choice. It stands to reason that a com-
bination of senolytic agents or alternative senolytics with higher potency to eliminate 
senescent cells of the joint may provide a more effective intervention.
3.2.2 Senolytic agents for the treatment of OP
3.2.2.1 Pre-clinical studies of senolytic agents for the treatment of OP
Several studies have located senescent cells in bone with aging [101, 102]. Farr 
et al. reported a higher expression of the senolytic markers p16Ink4a, p21Cip1, and 
p53, especially in osteocytes and myeloid cells, in aged mice compared to young 
mice [101]. Corresponding with the senescent osteocytes, the aged mice also 
demonstrated higher levels of SASP genes. Similar results were reported in bone 
biopsies from humans [103], suggesting that senescent osteocytes and SASPs may 
play an important role in aging-related OP. The role of senescent cells was further 
linked using a transgenic mouse line carrying a suicide transgene (INK-ATTAC) 
whereby p16Ink4a cells could be eliminated with the treatment of a drug (AP20187). 
The results showed that the AP20187 treated aged mice demonstrated clearance 
of senescent cells, lower osteoclast numbers, and improved trabecular bone of the 
spine and femur compared to the vehicle treated mice. In contrast, treatment with 
AP20187 in young mice did not change the bone quality. Further, this study showed 
similar results with oral senolytic treatment using Dasatinib and Quercetin, which 
led to significantly lower p16Ink4a mRNA expression and percentage of senescent 
osteocytes in bone compared to vehicle. They also found that the use of the JAK 
inhibitor Ruxolitinib reduced the SASP factors IL-6, IL-8, and PAI-1 with concomi-
tant improved spine and femur bone microarchitecture [104]. These results suggest 
that targeting senescent cells or SASP from senescent cells may reduce bone resorp-
tion and maintain or enhance bone formation. Therefore, senolytic drugs may be a 
promising alternative for treating aging-related OP.
3.2.2.2 Clinical studies of senolytic agents for the treatment of OP
Osteoporosis is a debilitating disease that significantly increases the risk of 
fracture, costing an estimated 13.8 billion USD annually, and directly increases 
the mortality rate by more than 30% in elderly Americans [105]. Pharmacological 
treatment for OP consists of two main categories; antiresorptive (bisphosphonates, 
estrogen agonists, etc.) and anabolic drugs, all with the intent to reduce fracture 
incidence [106]. However, current therapies are limited given the widely known side 
effects of chronic use, including the functional decline of the gastrointestinal tract 
and kidneys, osteonecrosis, esophageal cancer, osteogenic sarcoma, atrial fibrilla-
tion, and venous thromboembolism [107]. Further, anti-resorptive therapies, the 
general first-line approach, are uniformly associated with a concomitant reduction 
in bone formation, which prevents optimal fracture healing [108]. Thus, disease 
modifying alternatives with a better safety profile (or that require less dosing) is 
certainly needed for the treatment of OP. Like OA, cellular senescence is thought to 
be a fundamental driver of age-associated decline in a bone [104]. Several clinical 
trials are investigating the use of senotherapeutic drugs in the setting of OP.
In one Phase 2 randomized controlled trial, the senolytic drugs Dasatinib plus 
Quercetin and Fisetin alone are being tested in healthy elderly women aged 70+, 
when bone density is known to be reduced (ClinicalTrials.gov ID: NCT04313634). 
Bone turnover serum markers CTX-I and P2NP are measured with and without 
senolytic treatment. There are also two other active trials examining the effects of 
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age-related condition characterized by sarcopenia and decreased bone density. In 
these studies, primary endpoints include serum inflammatory markers and mobility 
based on a 6-min walk test.
Another promising senolytic drug is Metformin. There are at least four 
active trials measuring the effects of Metformin on pre-frail to frail patients 
(NCT03451006, NCT02570672, NCT04221750, NCT02325245). Primary endpoints 
in these studies are mobility and motor skills functions, including gait speed, 
balance ability, and grip strength test, geriatric depression score, and weight loss. 
Similar to OA trials, many of these trials are not complete, but there is compelling 
evidence that senolytic agents might benefit a litany of age-related skeletal decline. 
Details of preclinical animal studies and clinical trials of major senolytics in OA and 
OP and their mechanisms are summarized in Table 1 [59, 109].
4.  Mesenchymal stem cell (MSC)-based therapy for the treatment of 
aging-related musculoskeletal decline
4.1 Biological mechanisms of MSCs
Mesenchymal stem cells (MSCs) are present in a variety of human tissues, 
including bone marrow, adipose tissue, synovial tissue, and cord blood [110–112]. 
However, there is currently a lack of conclusive evidence regarding the potential 
biological mechanisms of MSCs for the treatment of aging-related musculoskeletal 
diseases. Understanding the function of MSCs opens up the possibility of develop-
ing robust MSC-based therapies for musculoskeletal regenerative medicine. Until 
now, there are two theories on the mechanism of function: (1) Direct adherence and 
incorporation into the host tissue and (2) trophic effects resulting from the MSC-
derived secretomes.
4.1.1 Direct adherence and incorporation of MSCs
One of the primary advantages of MSCs is their ability to interact with vari-
ous chemokine receptors (such as CXCR4, which is involved in MSC migration), 
integrins, selectins, and vascular cell adhesion molecule-1, to home damaged tissues 
[113–119]. The original hypothesis regarding the tissue regeneration mechanism of 
MSCs was that implanted cells would migrate directly to injury sites, where they 
would differentiate into functional cells and eventually promote repair of damaged 
connective tissue [120]. In support of this hypothesis, it has been reported that 
injected MSCs have the potential to adhere to the injury site and repair the host car-
tilage through regeneration, and interestingly, MSCs may also migrate to the injury 
site for tissue regeneration [121, 122]. However, whether the introduced MSCs are 
actually taken up into the host tissue and act directly on the damaged tissue has yet 
to be verified.
4.1.2 Trophic effects of MSCs
With decades of research on the underlying functionality of MSCs, it has been 
found that there exists a discrepancy between the frequency and duration of 
transplants and the remarkable healing power of MSCs [120]. Numerous studies 
have been conducted to resolve this conundrum, presenting the concept that MSCs 
possess the ability to maintain the proliferation and survival of certain cell types 
by secreting trophic factors, and regulating certain aspects of the immune system, 
thereby ushering MSC-based therapies into a new phase [123].
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Analysis of the MSC secretion and proteome has revealed various paracrine 
factors that can reduce apoptosis and inflammation and stimulate angiogenesis 
and self-renewal of progenitor cells [120]. Notably, MSCs are known to act as 
immunosuppressive cells that can alleviate inflammation and reduce monocyte 
activation by releasing anti-inflammatory factors, including interleukin-1 recep-
tor antagonist (IL-1ra) [124]. Pro-inflammatory cytokines, such as interleukin-1β 
(IL-1β), are widely known to play an essential role in OA progression [95] and 
IL-1ra confers an overall inhibitory effect on IL-1ß mediated inflammation and 
matrix degradation. Taken together, MSCs should confer a therapeutic potential in 
OA patients.
4.2  Properties and benefits of each type of MSCs on aging-related 
musculoskeletal decline
4.2.1 Bone marrow-derived MSCs (BM-MSCs)
4.2.1.1 Characteristics and advantages of BM-MSCs
Bone marrow is generally considered to be the home of hematopoietic stem 
cells and is known to contain MSCs as part of the stromal fraction [125]. BM-MSCs 
possess a high potential for cartilage repair due to their ready availability [126]. 
BM-MSCs have also been widely studied as a treatment for OP due to their high 
ability of osteogenesis.
4.2.1.2 Pre-clinical studies of BM-MSCs for OA
The effect of BM-MSCs on OA has been verified in numerous animal stud-
ies. Chiang et al. investigated the effects of intra-articular injection of allogeneic 
BM-MSCs in an in vivo rabbit OA model. They observed that the BM-MSCs trans-
plantation group had significantly better histological scores than the hyaluronic 
acid injection group [127]. Furthermore, Song et al. compared the efficacy of 
bone marrow mononuclear cells (BMMCs) and BM-MSCs in a sheep OA model 
and demonstrated that the BM-MSCs group had smaller lesions and a relatively 
smoother femoral condyle. They also reported that ICRS scores showed a greater 
improvement in the BM-MSCs group than the BMMCs and PBS (control) groups. 
They further stated that the results of histology showed fewer changes to cartilage 
and bone in the BM-MSCs group [128].
4.2.1.3 Pre-clinical studies of bm-MSCs for OP
Ichioka et al. demonstrated that direct injection of allogenic BM-MSCs into 
the bone marrow cavity of irradiated P6 sub-strain of senescence-accelerated 
mice (SAMP6), an osteoporotic mouse, resulted in inhibition of osteoblast and 
osteoclast formation in an age-dependent manner and promoted adipogenesis, 
increased trabecular bone and decreased bone mineral density [129]. Autologous 
BM-MSC transplantation has been reported to improve bone formation and 
strengthen osteoporotic bones in ovariectomy (OVX) -treated rabbits [130] and 
in estrogen-deficient goats, mimicking the postmenopausal OP that occurs in 
elderly women [110]. However, there is limited support for autologous BM-MSCs 
to treat OP in elderly patients because BM-MSCs isolated from the bone marrow 
of elderly patients have shown reduced proliferation and osteogenic capacity in 
vitro [131, 132].
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4.2.2 Adipose-derived MSCs (A-MSCs)
4.2.2.1 Characteristics and advantages of A-MSCs
MSCs were first reported in adipose tissue in 2001 [133] and have been touted 
as an attractive source of MSCs. Although A-MSCs have the advantage of being 
easier to isolate than BM-MSCs, [134] BM-MSCs have been shown to be prone to 
chondrogenic differentiation, both in vitro and in vivo [135]. Interestingly, however, 
it has also been reported that the addition of paracrine or cytokine factors increases 
the cartilage capacity of A-MSCs to a level comparable to that of BM-MSCs [136]. 
It is worth noting that the yield of A-MSCs and their proliferation and differentia-
tion ability is dependent on the site of tissue collection [137] and the age of the 
donor [138].
4.2.2.2 Pre-clinical studies of A-MSCs for OA
The effect of A-MSCs on OA has been investigated in numerous animal stud-
ies. Tang et al. compared the efficacy of three types of intra-articular injections, 
subcutaneous A-MSCs, visceral A-MSCs, and PBS (control), in a rat model of 
OA. Subcutaneous They found that A-MSCs injection decreased osteophyte 
and fibrous tissue formation compared to PBS or visceral A-MSCs. In addition, 
histologically, a smooth cartilage surface and distribution of lacunae and chon-
drocytes were observed in rats treated with subcutaneous A-MSCs [139]. Kuroda 
et al. verified the efficacy of A-MSCs for OA treatment using a rabbit model. They 
found that nearly normal cartilage was observed in the A-MSCs group, with less 
cartilage damage than in the control group. Further, the proportion of MMP-13- 
positive cells was significantly lower in sections of the A-MSCs group than in the 
control group [140].
4.2.2.3 Pre-clinical studies of A-MSCs for OP
The effects of A-MSCs have also been evaluated in OP animal models. Mirsaidi 
et al. performed the A-MSCs injection to SAMP6 mice and observed improvement 
of trabecular bone quality [141]. Additionally, Cho et al. studied the efficacy of 
human A-MSCs using OVX nude mice, showing that human A-MSCs could inhibit 
OVX-induced bone loss over eight weeks [142]. Furthermore, Ye et al. found that 
autologous A-MSCs enhanced bone regeneration in an OVX-induced rabbit model 
of OP, suggesting that this was due not only to autologous osteogenic differentiation 
but also to the promotion of osteogenesis and inhibition of adipogenesis through 
the activation of BMP-2 and BMPR-IB signaling pathways [143].
4.2.3 Synovium-derived MSCs (S-MSCs)
4.2.3.1 Characteristics and advantages of S-MSCs
In 2001, De Bari et al. isolated the first MSCs from the synovium of the human 
knee joint [144]. Since then, S-MSCs have attracted attention because they are 
more readily accessible, possess a higher growth rate, and are less immunogenic 
compared with MSCs from other origins [145]. Sakaguchi et al. compared the 
yield, expandability, differentiation potential, and epitope profiles of human MSCs 
derived from five different mesenchymal tissue sources: bone marrow, synovium, 
periosteum, adipose tissue, and muscle, and concluded that S-MSCs had the highest 
capacity for chondrogenesis [146].
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4.2.3.2 Pre-clinical studies of S-MSCs for OA
The beneficial effects of S-MSCs in promoting cartilage regeneration have been 
reported in pig, [146] leporin, [135] and canine models [147]. In a recent systematic 
review of in vivo studies on synovium-derived mesenchymal stem cell transplanta-
tion for cartilage regeneration, To et al. showed, in 4 human and 16 animal articles, 
that S-MSCs possess overall good chondrogenic potential and positive effect for 
treating chondral lesions and preventing OA [148]. Ozeki et al. found that intra-
articular injection of S-MSCs in a rat model of OA could inhibit the OA progression 
and attenuate synovitis when administered once a week instead of a single dose 
[149]. Accumulating evidence that S-MSCs possess a strong chondrogenic potential 
and the fact that MSCs derived from synovial tissue is specific to target joints have 
led to a growing interest in the application of S-MSCs for a stem cell therapy of 
knee OA.
4.2.3.3 Pre-clinical studies of S-MSCs for OP
As it pertains to osteogenic potential, Sakaguchi et al. showed that S-MSCs pos-
sessed a higher capacity than adipose tissue- and muscle-derived cells, comparable 
to bone marrow-, and periosteal-derived [150]. However, S-MSC-based therapy for 
OP has yet to be well investigated.
4.2.4  Muscle-derived stem cells (MDSCs)/muscle-derived stem progenitor cells 
(MDSPCs)
4.2.4.1 Characteristics and advantages of MDSCs/MDSPCs
MDSCs/MDSPCs are pluripotent cells isolated from postnatal skeletal muscle via 
established preplating techniques. They are characterized by multiple critical features 
such as long-term proliferation/self-renewing capacity, resistance to oxidative and 
inflammatory stress, and multilineage differentiation potential [151–153]. Recently, it 
has been shown that skeletal muscle-derived MSCs from OA patients exhibit superior 
biological properties compared to the bone-derived MSCs counterpart, making 
them a promising candidate for autologous stem cell therapy [154]. MDSPCs have 
been shown to improve the regenerative capacity of various tissues, including bone, 
cartilage, skeletal muscle, and cardiac muscle, by promoting angiogenesis [155–159].
Of note, several studies have investigated differences in the proliferation and 
differentiation ability of MDSCs by sex and age [158, 160, 161]. It has been shown 
that male murine MDSPCs displayed higher chondrogenic differentiation capacity 
and cartilage regeneration potential than female murine MDSPCs [160]. Similarly, 
Corsi et al. showed that the osteogenesis of male murine MDSPCs was superior to 
that of female MDSPCs [162]. Furthermore, our group has recently found that in 
human MDSPCs, male MDSPCs possess a greater ability to undergo chondrogenesis 
and osteogenesis than female MDSPCs [161].
Our group, on the other hand, have reported that not only donor but also host 
sex affects bone regeneration; male murine hosts showed a greater amount of 
MDSPC-mediated ectopic bone formation and cranial defect healing than did 
female hosts [163].
4.2.4.2 Pre-clinical studies of MDSCs/MDSPCs for OA
An interesting study by Kuroda et al. indicated that local delivery of BMP-4 
by genetically engineered MDSCs promoted chondrogenesis with a significant 
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improvement of articular cartilage repair in rats [164]. This suggests that MDSCs 
are advantageous concerning chondrogenic differentiation potential. Furthermore, 
Matsumoto et al. demonstrated in a rat model that MDSCs therapy with sFlt-1 and 
BMP-4 promotes chondrogenesis in OA, and inhibits cartilage resorption by inhibit-
ing angiogenesis, thus enabling sustained cartilage regeneration and repair [165].
4.2.4.3 Pre-clinical studies of MDSCs/MDSPCs for OP
Our group isolated young and old populations of gender-matched human 
muscle-derived stem cells (hMDSCs) to examine the effect of age on osteogenic 
differentiation using a critical-size calvarial bone defect mouse model. In addi-
tion, the effect of donor and host age on hMDSC-mediated bone regeneration was 
investigated. We showed that donor age did not impair hMDSC-mediated bone 
regeneration, while host age had the adverse effect. We also found that hMDSCs 
form functional bone regardless of the age of the donor or host, suggesting that 
these cells are a promising resource for bone regeneration [166].
4.3  Clinical studies of MSC-based therapy for the treatment of aging-related 
musculoskeletal decline
4.3.1 Clinical studies of MSC-based therapy for OA
More than 30 clinical trials on the administration of intra-articular MSCs for 
the treatment of OA have been completed to date, including randomized controlled 
trials, retrospective studies, and cohort studies (https://www.clinicaltrials.gov/), 
and most of the published results have shown clinical benefit [111, 112, 167–178]. 
Currently, B-MSCs and A-MSCs are the most commonly used cell sources in clinical 
trials for OA, [179] however, finding an optimal treatment with MSCs is challenging 
due to the great diversity of patient populations, delivery methods, cell numbers, 
culture expansion methodology, and follow-up periods.
Until now, no clinical trials on the benefit of intra-articular administration of 
S-MSCs in patients with OA have been published. Interestingly, however, Sekiya et 
al. found that arthroscopic S-MSCs transplantation improved the clinical outcome 
of knees with articular cartilage defects at a mean follow-up of 52 months in 10 
patients based on MRI, histology, and clinical outcome score evaluation [180]. 
Furthermore, Shimomura et al. conducted the first human pilot study of implanting 
scaffold-free tissue-engineered constructs generated from S-MSCs to the injury site 
for five patients with symptomatic knee cartilage lesions, demonstrating that self-
assessed clinical scores for pain, symptoms, activities of daily living, sports activi-
ties, and quality of life improved significantly at 24 months postoperatively, with 
no serious adverse events. In addition, second-look arthroscopy and MRI confirmed 
complete defect filling in all cases, and biopsy of the regenerated cartilage showed 
that the repair tissue consisted of hyaline cartilage [181]. These results showed that 
implantation of S-MSCs could repair articular cartilage damage and prevent its 
progression to OA, and therefore, future clinical applications in patients with OA 
may be promising. There is also evidence that, in a phase I/II study, repeated admin-
istration of umbilical cord-derived-MSCs improved safety and clinical outcomes for 
long-term pain in patients with knee OA [112].
4.3.2 Clinical studies of MSC-based therapy for OP
A recent Phase 1 clinical trial has been conducted using fucosylated BM-MSCs 
for patients with OP. In this study, autologous BM-MSCs were harvested 30 days 
17
Interventional Strategies to Delay Aging-Related Dysfunctions of the Musculoskeletal System
DOI: http://dx.doi.org/10.5772/intechopen.97311
Author details
Naomasa Fukase, Ingrid K. Stake, Yoichi Murata, William S. Hambright, 
Sudheer Ravuri, Marc J. Philippon and Johnny Huard*
Steadman Philippon Research Institute, Vail, CO, USA
*Address all correspondence to: jhuard@sprivail.org
prior to the infusion and cultured under good manufacturing practice (GMP) 
conditions to purify and obtain mesenchymal cell established dose range. This study 
is ongoing, and the recruitment of participants is currently closed. (ClinicalTrials.
gov ID: NCT02566655).
Although the use of MSC products for the treatment of aging-related skeletal 
disorders is becoming increasingly prevalent, well-designed studies are imperative 
to conclusively prove their clinical benefits and identify the optimal indications, cell 
sources, delivery methods, and doses.
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